NCT07909954
Accelerated Theta-Burst Stimulation for Refractory Central Post-Stroke Pain
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Feasibility, as measured by the proportion of participants who can complete 80% of stimulation sessions
Timeframe: From the time of stimulation (day 1) until end of stimulation (day 5)
Feasibility, as measured by proportion of participants who complete 80% of stimulation days
Timeframe: From the time of stimulation (day 1) until end of stimulation (day 5)
Feasibility, as measured by consent rate of those screened
Timeframe: Baseline
Safety, as measured by the number of adverse events
Timeframe: Day 90
Pain as measured by Visual Analog Scale (VAS)
Timeframe: Baseline, 7 days, and 90 days
Secondary (1)
Thalamo-cortical disconnection index (TCDI), derived from MRI
Arms and interventions
High-dose aiTBSExperimental
Participants receive high-dose accelerated intermittent theta burst stimulation consisting of 10 sessions per day (18,000 pulses/day) over 5 consecutive days targeting the ipsilesional motor cortex.
Low-dose aiTBSExperimental
Participants receive low-dose accelerated intermittent theta burst stimulation consisting of 5 sessions per day (9,000 pulses/day) over 5 consecutive days targeting the ipsilesional motor cortex.
Devices: High-dose accelerated intermittent theta burst stimulation (aiTBS), Low-dose accelerated intermittent theta burst stimulation (aiTBS)